Blog
RSS FeedPosted by Michael Wonder on 16 May 2024
It is time to reconsider the 3% discount rate
15 May 2024 - Health technology assessment guidance often recommends a 3% real annual discount rate, the appropriateness of which ...
Posted by Michael Wonder on 13 May 2024
Boehringer Ingelheim expands access to adalimumab-adbm injection, the company's biosimilar to Humira
13 May 2024 - Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient ...
Posted by Michael Wonder on 13 May 2024
PHARMAC shares the agenda items for the upcoming Rare Disorders Committee meeting (May 2024)
13 May 2024 - PHARMAC is sharing what medicine applications will be considered at the Rare Disorders Advisory Committee meeting ...
Posted by Michael Wonder on 13 May 2024
Zai Lab announces approval of Augtyro (repotrectinib) for patients with ROS1 positive NSCLC by China’s NMPA
12 May 2024 - The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro achieved a high response ...
Posted by Michael Wonder on 13 May 2024
First ever life-saving treatment for rare heart condition available on the NHS
13 May 2024 - NHS patients with a life-threatening heart condition are set to benefit from a cutting-edge new medicine ...
Posted by Michael Wonder on 13 May 2024
Dupixent (dupilumab) sBLA accepted for FDA priority review for treatment of adolescents with chronic rhinosinusitis with nasal polyposis
13 May 2024 - If approved, Dupixent would be the first treatment in the US indicated for adolescents aged 12-17 years ...
Posted by Michael Wonder on 13 May 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease (final guidance)
8 May 2024 - NICE has published final evidence-based recommendations on the use of remdesivir (Veklury) and tixagevimab and cilgavimab ...
Posted by Michael Wonder on 13 May 2024
A systematic review on the appropriate discounting rates for the economic evaluation of gene therapies: whether a specific approach is justified to tackle the challenges
10 May 2024 - Discounting the cost and effect for health intervention is a controversial topic over the last two decades. ...
Posted by Michael Wonder on 13 May 2024
Australians benefit from new life changing medicines added to the PBS
13 May 2024 - Women with endometrial cancer and people with itching associated with chronic kidney disease will benefit from ...
Posted by Michael Wonder on 12 May 2024
Moderna announces update on investigational RSV vaccine
10 May 2024 - US FDA has informed Moderna that due to administrative constraints, the agency will not complete its review ...
Posted by Michael Wonder on 11 May 2024
Health Canada approves Keytruda for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
9 May 2024 - Approval is based on the Phase 3 KEYNOTE-966 Trial. ...
Posted by Michael Wonder on 10 May 2024
SN Bioscience receives FDA fast track designation for small cell lung cancer
9 May 2024 - SN Bioscience announced on 7 May that the FDA has granted fast track designation for small cell ...
Posted by Michael Wonder on 10 May 2024
Tests could lead to fewer people having unnecessary chemotherapy after surgery for early breast cancer
10 May 2024 - More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated ...
Posted by Michael Wonder on 10 May 2024
Novartis receives FDA breakthrough therapy designation for Scemblix in first-line CML
10 May 2024 - Breakthrough therapy designation was granted based on positive data from the Phase 3 ASC4FIRST study, in which ...
Posted by Michael Wonder on 10 May 2024
When will Canada have national pharmacare?
22 April 2024 - Canadians support it, public health demands it, now policy makers must deliver it. ...
Posted by Michael Wonder on 10 May 2024
Agenda for the July 2024 PBAC meeting (version 3)
10 May 2024 - The Department of Health has published a revised agenda for the July 2024 PBAC meeting. ...